6
March 2013 Laboratory Focus www.laboratoryfocus.ca
APPOINTMENTS
CO2 Solutions Inc. has appointed Dr. Louis Fradette as chief technology officer and senior vice presi-
dent, Process Engineering. Dr. Fradette has over 25 years’ experience in chemical engineering, engineering development and project management. He has worked in R&D in both the public and private sectors, including the petrochemicals, oil and gas industries. In his new role, Dr. Fradette will lead development and application of CO2 Solutions’ carbon capture technology for the
company’s Alberta oil sands project. Dr. Fradette has a Master’s degree in Chemical Engineering from Laval University in Québec City, a PhD in Process Engineering from l’Institut National Polytechnique de Lorraine in France, and a PhD in Chemical Engineering from the École polytechnique de Montréal, where he is currently an associate professor in Chemical Engineering. Imaging Dynamics Company, Ltd. announces the appointment of Anna Lentz, CGA, MBA, as chief financial officer. Lentz has broad experience in the financial management of private and public companies in the oil and gas, mining, engineering, and manufacturing sectors. Currently, she is the principal of a privately owned financial consulting firm that provides the financial management and required controls for the success of its small to mid-sized clients. Lentz replaces John Choy who acted as interim CFO for the company. CHU Sainte-Justine appoints Dr. Alain Moreau as its director. Over the past 12 years, Dr. Moreau has
Canadian Society for Chemical Technology Professional Development
discount members for CIC/CSCT
Advance your professional knowledge and further your Career
Laboratory Safety course Lean Sigma course Course Dates:
June 3–4, 2013 Edmonton, Alta. September 17–18, 2013 Toronto, Ont. Course outlines and registration at
www.cheminst.ca/profdev
cumulated a number of achievements under the various key positions he has held, including owner of the Technopôle rehabilitation project (to open in 2015), associate director of Academic Affairs at the Research Center, research scientist in musculoskeletal disorders, and co-director of the CHUSJ’s Department of Dentistry. Dr. Moreau is a professor at the Université de Montréal, in the Department of Stomatology at the Faculty of Dentistry and in the Department of Biochemistry at the Faculty of Medicine. He holds a Bachelor of Science in Biology from the Université de Montréal, a Master’s of Science in Applied Microbiology from the Institut Armand-Frappier, and a PhD in Microbiology and Immunology from the Université de Montréal. Xenon Pharmaceuticals Inc. has appointed Gary J. Bridger, PhD, as executive vice president of Research and Development. Dr. Bridger has spent over 20 years in the life sciences industry including positions at Johnson Matthey, AnorMED and Genzyme. Dr. Bridger was a primary member of the team that managed AnorMED’s acquisition by Genzyme for US$580 million. Previously, he was a partner with Ventures West Capital Management and he currently serves on the Scientific Advisory Board of Alectos Pharmaceuticals. He has co-authored over 90 peer-reviewed publications and 40 granted US patents, mainly in the chemokine receptor antagonists field. Dr. Bridger received his PhD in Organic Chemistry from the University of Manchester UK and completed a post-doctoral fellowship at Boston College. Dr. Rachael Ritchie has been appointed director of Business Development at Genome BC. Over the past 20 years, Dr. Ritchie has held numerous positions for various
academic and government institutions. She began as a molecular geneticist for the Food, Fisheries and Aquaculture Department Research and Productivity Council in New Brunswick, where she then became department head. From there she went to project manage the International Chair in EcoInnovation at the UniverSUD Paris/ Université de Versailles in France. Previously, Dr. Ritchie was a policy analyst in the Science Technology Policy Department at the Organization for Economic Co-operation and Development (OECD). Dr. Richie has a Bachelor of Science in biochemistry from UBC, a PhD in clinical
medicine from Oxford University and completed a post-doctoral fellowship at Harvard University at the Boston Children’s Hospital. The University of British Columbia (UBC) Faculty of Pharmaceutical Sciences announces the appointment of Dr. Corey Nislow to the faculty as Associate Professor. Dr. Nislow has both academic and corporate experience, being the first to identify and the first to clone a human mitotic kinesin during his PhD and spending five years at three different biotechnology companies in the San Francisco Bay area. His current research includes using model organisms to understand the mechanism of action of human therapeutics, using high-throughput cell biology to investigate drug synergy, and developing technologies for understanding the relationship between chromatic structure and transcriptional regulation. Dr. Nislow will be joining UBC from the University of Toronto where he served as Associate Professor with the Banting and Best Department of Medical Research and as Director of the Donnelly Sequencing Centre.
